Piromidic acid
Piromidic acid is an antibacterial agent. Piromidic acid is active against gramnegative bacteria and staphylococci and can be used for the research of intestinal, urinary, and biliary tract infections[1][2].
Product Specifications
CAS Number
19562-30-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Antibiotic; Bacterial
Type
Natural Products
Related Pathways
Anti-infection
Applications
COVID-19-immunoregulation
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/Piromidic-acid.html
Purity
98.96
Solubility
H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 80°C)
Smiles
O=C(C1=CN(CC)C2=NC(N3CCCC3)=NC=C2C1=O)O
Molecular Formula
C14H16N4O3
Molecular Weight
288.30
Precautions
H302, H315, H319, H335
References & Citations
[1]Sekine Y, et al. Metabolism in rats and man of piromidic acid, a new antibacterial agent. Xenobiotica. 1976 Mar;6 (3) :185-8.|[2]Shimizu M, et, al. Pipemidic acid, a new antibacterial agent active against Pseudomonas aeruginosa: in vitro properties. Antimicrob Agents Chemother. 1975 Aug;8 (2) :132-8.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Natural Products
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC940178-100 1x 100 µL
CD50 (ICAM-3) (186-2G9), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC401037-500 1x 500 µL
CD44 Standard (DF1485), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740857-100 1x 100 µL
WT1 (Wilm's Tumor 1) (WT1/857), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC401700-500 1x 500 µL
CD44v4 (Marker of Tumor Metastasis) (CD44v4/1700R), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC942422-500 1x 500 µL
BOB.1 (B-Cell Marker) (BOB1/2422), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880394-500 1x 500 µL
Cytokeratin 19 (Ks19.1), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details